Abstract:e16133 Background: Combination treatment with an immune checkpoint inhibitor and an anti-VEGF antibody is recommended as the standard care for advanced hepatocellular carcinoma (HCC). However, the efficacy of systemic therapy is less than satisfactory in BCLC stage C. Transarterial chemoembolization (TACE) combined with systemic therapy may synergistically improve patients’ clinical outcomes and obtain survival benefits. Intra-arterial infusion of Sintilimab and Bevacizumab has not been assessed previously. This study aimed to evaluate the safety and efficacy of TACE combined with the intra-arterial infusion of Sintilimab and Bevacizumab in patients with BCLC stage C HCC. Methods: This prospective, single-arm phase II study recruited 16 patients with advanced HCC. Main inclusion criteria: aged ≥ 18 years; a confirmed HCC (BCLC stage C) based on the ALSLD with either pathological or imaging findings; no previous systemic/locoregional anticancer treatment; Child-Pugh score ≤7; ECOG performance status: 0-1. Patients were treated with TACE (30-40mg of pirarubicin, 30-40mg of lobaplatin, and lipiodol) plus Sintilimab (200mg, intra-arterial infusion, d1, Q3W) and Bevacizumab (7.5mg/kg, intra-arterial infusion, d1, Q3W) for four cycles, followed by maintenance therapy with Sintilimab (200mg, intravenously, d1, Q3W) and Bevacizumab (15mg/kg, intravenously, d1, Q3W) to a maximum total cycle of eighteen unless any evidence of disease progression or unacceptable side effects. The primary endpoint was objective response rate (ORR) (assessed with mRECIST v1.1) and the secondary endpoints included disease control rate (DCR), time to progress (TTP), progression-free survival (PFS), duration of response (DOR), overall survival (OS) and safety. Drug safety was investigated according to CTCAE (version 5.0). Results: From September 2021 to December 2022, 16 patients with a median age of 52 years (range:38 -73) were enrolled. 12 (75%) patients with HBV infection and 6 (38%) with extrahepatic metastasis. 14 (88%) patients were classified as Child-Pugh A class. With a median follow-up of 5.4 months (range 3.9-14.3), the ORR was 63% (95%CI, 36.4%- 84.8%) with 3 CR and 7 PR per mRECIST v1.1, and the DCR was 69% (95%CI, 41.3%-89.0%). The median PFS was not reached. Adverse events in 31% of 16 patients were hypertension (3, 19%), fatigue (1, 6%), and proteinuria (1, 6%). The most common adverse event of grade 3 was hypertension (2, 13%). There were no treatment-related serious adverse events. Conclusions: TACE combined with the intra-arterial infusion of Sintilimab and Bevacizumab as the first-line strategy for advanced HCC patients (BCLC stage C) demonstrated a promising value by improving ORR, with acceptable side effects. Clinical trial information: NCT04796025 .

A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma.

Indocyanine Green Clearance in Evaluating the Recovery of Liver Reserve Function after Superselective Transarterial Chemoembolization

Drug-eluting Beads Transarterial Chemoembolization by CalliSpheres is Effective and Well Tolerated in Treating Intrahepatic Cholangiocarcinoma Patients

Change of indocyanine green clearance ability and liver function after transcatheter intraarterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort study

Change of Indocyanine Green Clearance Ability and Liver Function after Transcatheter Intra-Arterial Therapies and Its Impact on Outcomes of Resectable Hepatocellular Carcinoma: a Retrospective Cohort Study.

TACE combined with the intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: A prospective, single-arm, phase II study.

Iodine-125 Implantation Plus Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma of 3–5 Cm: A Propensity Score Matching Study

A novel stratification scheme combined with internal arteries in CT imaging for guiding postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study

Transarterial Chemoembolization Treatment in the Management of BCLC C Stage Hepatocellular Carcinoma: A Large Real-World Observational Study of 885 Cases

A Retrospective Cohort Analysis of Transarterial Chemoembolization for Hepatocellular Cancer at a Tertiary Center in Switzerland

I-125 Seeds Brachytherapy with Transcatheter Arterial Chemoembolization for Subcapsular Hepatocellular Carcinoma

Survival Analysis of TACE Monotherapy Vs. Combination Therapy in BCLC B and C Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma

Single-Agent Versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase Ii Trial

Protocol of REACH-01: a Single-Arm, Open Label, Prospective Study of HAIC Sequential TAE Combined with Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Drug-eluting Beads Transarterial Chemoembolization with CalliSpheres Microspheres for Treatment of Unresectable Intrahepatic Cholangiocarcinoma

Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.

Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined With Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma

TACE by using microspheres and lipiodol for the treatment of hepatocellular carcinoma: analysis of short-term efficacy

[Value of CIK in the Treatment of TACE Combined with RFA for HCC in Long-Term Survival and Prognostic Analysis].

Effect of transcatheter arterial chemoembolization combined with radiofrequency ablation and cytokine-induced killer cells infusion on small hepatocellular carcinoma